Ocular Therapeutix (OCUL) News Today $7.17 -0.36 (-4.78%) As of 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period What is William Blair's Forecast for OCUL Q1 Earnings?Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) - Equities research analysts at William Blair issued their Q1 2025 earnings estimates for shares of Ocular Therapeutix in a research report issued on Tuesday, April 8th. William Blair analyst L. Hanbury-Brown forecasts that the biopharmaceuticaApril 13 at 7:28 AM | marketbeat.comVanguard Group Inc. Purchases 99,730 Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL)Vanguard Group Inc. lifted its position in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) by 1.2% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 8,483,913 shares of the biopApril 13 at 3:40 AM | marketbeat.comQ1 Earnings Estimate for OCUL Issued By William BlairApril 13 at 1:25 AM | americanbankingnews.comOcular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)April 11, 2025 | globenewswire.comWilliam Blair starts Ocular Therapeutix stock with OutperformApril 10, 2025 | uk.investing.comOcular Therapeutix (NASDAQ:OCUL) Earns Outperform Rating from Analysts at William BlairWilliam Blair assumed coverage on Ocular Therapeutix in a research note on Tuesday. They issued an "outperform" rating on the stock.April 10, 2025 | marketbeat.comOcular Therapeutix (NASDAQ:OCUL) Receives Buy Rating from Needham & Company LLCNeedham & Company LLC reissued a "buy" rating and issued a $15.00 price target on shares of Ocular Therapeutix in a research report on Tuesday.April 10, 2025 | marketbeat.comWilliam Blair Initiates Coverage of Ocular Therapeutix (OCUL) with Outperform RecommendationApril 9, 2025 | msn.comOcular Therapeutix (OCUL) Receives a Buy from NeedhamApril 9, 2025 | markets.businessinsider.comOcular Therapeutix initiated with an Outperform at William BlairApril 8, 2025 | msn.comNottingham Advisors Inc. Has $835,000 Stake in Ocular Therapeutix, Inc. (NASDAQ:OCUL)Nottingham Advisors Inc. lowered its holdings in Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) by 47.3% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 97,828 shares of the biopharmaceuticalApril 5, 2025 | marketbeat.comOcular Therapeutix (NASDAQ:OCUL) Shares Up 4.9% - Should You Buy?Ocular Therapeutix (NASDAQ:OCUL) Trading 4.9% Higher - Here's What HappenedApril 4, 2025 | marketbeat.comOcular Therapeutix (NASDAQ:OCUL) Trading Down 5.8% - Time to Sell?Ocular Therapeutix (NASDAQ:OCUL) Trading Down 5.8% - What's Next?April 3, 2025 | marketbeat.comRaymond James Financial Inc. Makes New $1.72 Million Investment in Ocular Therapeutix, Inc. (NASDAQ:OCUL)Raymond James Financial Inc. acquired a new position in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 201,623 shares of the biopharmaceApril 2, 2025 | marketbeat.comOcular Therapeutix, Inc. (NASDAQ:OCUL) Receives Consensus Recommendation of "Moderate Buy" from AnalystsOcular Therapeutix, Inc. (NASDAQ:OCUL - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the eight analysts that are presently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a hold rating and seven have issued a buy rating onApril 2, 2025 | marketbeat.comOcular Therapeutix™ to Participate in Two Investor Conferences in AprilMarch 31, 2025 | globenewswire.comArtisan Partners Limited Partnership Purchases 278,610 Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL)Artisan Partners Limited Partnership raised its holdings in Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) by 26.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,334,702 shares of the biopharmaceutical company'sMarch 30, 2025 | marketbeat.comOcular Therapeutix added to Analyst Current Favorites list at Raymond JamesMarch 27, 2025 | markets.businessinsider.comOcular Therapeutix, Inc. (NASDAQ:OCUL) Holdings Raised by Rosalind Advisors Inc.Rosalind Advisors Inc. lifted its stake in Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) by 27.5% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 1,128,700 shares of the biopharmaceutical company's stock after purchasing aMarch 23, 2025 | marketbeat.comVictory Capital Management Inc. Boosts Stock Position in Ocular Therapeutix, Inc. (NASDAQ:OCUL)Victory Capital Management Inc. boosted its stake in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) by 300.4% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 68,871 shares of the biopharmaceMarch 22, 2025 | marketbeat.comOcular Therapeutix (NASDAQ:OCUL) Shares Gap Up - What's Next?Ocular Therapeutix (NASDAQ:OCUL) Shares Gap Up - What's Next?March 19, 2025 | marketbeat.comRoyal Bank of Canada Begins Coverage on Ocular Therapeutix (NASDAQ:OCUL)Royal Bank of Canada began coverage on Ocular Therapeutix in a research report on Tuesday. They set an "outperform" rating and a $17.00 price objective for the company.March 19, 2025 | marketbeat.com3OCUL : What 4 Analyst Ratings Have To Say About Ocular TherapeutixMarch 18, 2025 | benzinga.comRBC Capital Initiates Coverage of Ocular Therapeutix (OCUL) with Outperform RecommendationMarch 18, 2025 | msn.comOcular Therapeutix (OCUL) Gets a Buy from RBC CapitalMarch 18, 2025 | markets.businessinsider.comOcular Therapeutix initiated with an Outperform at RBC CapitalMarch 18, 2025 | markets.businessinsider.comWhy Ocular Therapeutix Was Bumping Higher This WeekMarch 14, 2025 | fool.comOcular Therapeutix (NASDAQ:OCUL) Shares Up 9.7% - Should You Buy?Ocular Therapeutix (NASDAQ:OCUL) Stock Price Up 9.7% - Here's WhyMarch 12, 2025 | marketbeat.comOcular Therapeutix (NASDAQ:OCUL) Earns Buy Rating from Analysts at Needham & Company LLCNeedham & Company LLC assumed coverage on shares of Ocular Therapeutix in a research note on Tuesday. They set a "buy" rating and a $15.00 target price for the company.March 12, 2025 | marketbeat.comOcular Therapeutix initiated with a Buy at NeedhamMarch 11, 2025 | markets.businessinsider.comOcular rises as Needham issues new Buy on lead candidateMarch 11, 2025 | msn.comNeedham Initiates Coverage of Ocular Therapeutix (OCUL) with Buy RecommendationMarch 11, 2025 | msn.comEssex Investment Management Co. LLC Cuts Holdings in Ocular Therapeutix, Inc. (NASDAQ:OCUL)Essex Investment Management Co. LLC trimmed its holdings in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) by 12.7% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 387,248 sharesMarch 10, 2025 | marketbeat.comHC Wainwright Cuts Earnings Estimates for Ocular TherapeutixOcular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) - Research analysts at HC Wainwright lowered their Q1 2025 EPS estimates for Ocular Therapeutix in a report released on Tuesday, March 4th. HC Wainwright analyst Y. Chen now expects that the biopharmaceutical company will post earnings of ($0.3March 7, 2025 | marketbeat.comOcular Therapeutix, Inc. (NASDAQ:OCUL) Receives Average Rating of "Moderate Buy" from AnalystsShares of Ocular Therapeutix, Inc. (NASDAQ:OCUL - Get Free Report) have earned an average rating of "Moderate Buy" from the six ratings firms that are currently covering the firm, Marketbeat reports. One research analyst has rated the stock with a hold recommendation and five have issued a buy reMarch 7, 2025 | marketbeat.comOcular Therapeutix: Axpaxli's Dual Trial Strategy And Blockbuster PotentialMarch 6, 2025 | seekingalpha.comOcular Therapeutix (NASDAQ:OCUL) Trading Up 3.3% - Should You Buy?Ocular Therapeutix (NASDAQ:OCUL) Trading Up 3.3% - Here's WhyMarch 5, 2025 | marketbeat.comTruist Financial Corp Acquires Shares of 50,000 Ocular Therapeutix, Inc. (NASDAQ:OCUL)Truist Financial Corp acquired a new stake in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor acquired 50,000 shares of the biopharmaceutical company's stock, valMarch 5, 2025 | marketbeat.comOcular Therapeutix shares tumble on earnings missMarch 5, 2025 | in.investing.comScotiabank Sticks to Their Buy Rating for Ocular Therapeutix (OCUL)March 5, 2025 | markets.businessinsider.comOcular Therapeutix, Inc. (NASDAQ:OCUL) Q4 2024 Earnings Call TranscriptMarch 5, 2025 | msn.comOcular Therapeutix Stock Sees Worst Day In Nearly A Year On Q4 Miss, But Retail Sees A ComebackMarch 4, 2025 | msn.comHC Wainwright Reaffirms Buy Rating for Ocular Therapeutix (NASDAQ:OCUL)HC Wainwright reissued a "buy" rating and issued a $15.00 price objective on shares of Ocular Therapeutix in a research note on Tuesday.March 4, 2025 | marketbeat.comOcular Therapeutix reports Q4 EPS (29c), consensus (22c)March 3, 2025 | markets.businessinsider.comOcular Therapeutix outlines AXPAXLI NDA submission timeline with SOL-1 topline data expected Q1 2026March 3, 2025 | msn.comOcular Therapeutix Shares Drop After Wider-Than-Expected 4Q LossMarch 3, 2025 | marketwatch.comOcular Therapeutix Sees Unusually High Options Volume (NASDAQ:OCUL)Ocular Therapeutix, Inc. (NASDAQ:OCUL - Get Free Report) was the recipient of some unusual options trading on Monday. Stock investors bought 7,643 call options on the stock. This is an increase of 1,707% compared to the average daily volume of 423 call options.March 3, 2025 | marketbeat.comOcular Therapeutix (NASDAQ:OCUL) Shares Gap Down on Disappointing EarningsOcular Therapeutix (NASDAQ:OCUL) Shares Gap Down After Earnings MissMarch 3, 2025 | marketbeat.comOcular Therapeutix (NASDAQ:OCUL) Releases Quarterly Earnings ResultsOcular Therapeutix (NASDAQ:OCUL - Get Free Report) posted its quarterly earnings data on Monday. The biopharmaceutical company reported ($0.29) earnings per share for the quarter, missing the consensus estimate of ($0.24) by ($0.05). Ocular Therapeutix had a negative return on equity of 45.18% and a negative net margin of 283.74%.March 3, 2025 | marketbeat.comPravin Dugel Sells 21,475 Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL) StockOcular Therapeutix, Inc. (NASDAQ:OCUL - Get Free Report) insider Pravin Dugel sold 21,475 shares of the firm's stock in a transaction on Monday, February 24th. The shares were sold at an average price of $6.87, for a total transaction of $147,533.25. Following the completion of the sale, the insider now owns 3,520,318 shares in the company, valued at $24,184,584.66. The trade was a 0.61 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this hyperlink.February 27, 2025 | marketbeat.com Remove Ads Get Ocular Therapeutix News Delivered to You Automatically Sign up to receive the latest news and ratings for OCUL and its competitors with MarketBeat's FREE daily newsletter. Email Address OCUL Media Mentions By Week OCUL Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. OCUL News Sentiment▼0.660.79▲Average Medical News Sentiment OCUL News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. OCUL Articles This Week▼114▲OCUL Articles Average Week Remove Ads Get Ocular Therapeutix News Delivered to You Automatically Sign up to receive the latest news and ratings for OCUL and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies GRFS News Today CYTK News Today VRNA News Today ELAN News Today PCVX News Today RYTM News Today PTCT News Today ZLAB News Today ACLX News Today RARE News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:OCUL) was last updated on 4/16/2025 by MarketBeat.com Staff From Our PartnersTrump Makes Major Crypto AnnouncementTrump Ends the “War on Crypto” I expect it to pump the market, which is why I'm recommending ONE coin to al...Crypto 101 Media | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredDOGE tax surpriseElon Musk's DOGE agents have some very strange plans for the IRS... Recently, it emerged that our tax auth...Altimetry | SponsoredIs it CRAZY to still want reliable profits, despite this market?Larry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredFirst look: The $3,500 iPhoneDid you hear that just before Trump's tariffs took effect, Apple sent five cargo planes packed with MacBooks a...Stansberry Research | SponsoredMarkets in Chaos? Here’s What to Do.Wall Street's on edge with tariffs. And volatility? It's not slowing down. You've seen the headlines… Bu...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ocular Therapeutix, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ocular Therapeutix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy OCUL Stock Free OCUL Stock Alerts